Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42XUnusual Whales·11 hours agoIXHL+3.59%
Scanning the Market's Corners: Who's Faking It and Who's Making ItGlobal Report·14 hours agoTALO-2.54%XP+4.28%
Beyond the Mega-Caps: U.S. Small-Cap Pharma, E&P Operators, and Tactical ETFs in FocusGlobal Report·Aug 19 at 05:11 AMRRC-0.63%RDACR0.00%
Incannex wins approval of overseas findings, secures A$5.1 million R&D tax refundPUBT·Aug 11 at 06:32 AMIXHL+3.59%
Survival of the Fittest: How Whirlpool and Yelp are Navigating 2026Global Report·Aug 8 at 04:21 AMMOH+0.57%IXHL+3.59%
Under-the-Radar Movers: From Warby Parker's Smart Glasses to Teck's OverhaulGlobal Report·Jul 29 at 04:19 AMXPON-15.00%RL-2.22%
Incannex starts screening patients in Phase 2 DReAMzz trial of IHL-42X for sleep apneaPUBT·Jul 23 at 06:32 AMIXHL+3.59%
